Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.
Valeant yesterday confirmed that they are planning on making an improved, bigger offer for Allergan after their initial unsolicited $46 billion takeover offer was rejected. US pharmaceutical company, Allergan, who are best-known for their Botox, rejected Valeant and investor Bill Ackman’s Pershing Square Capital Management’s offer earlier this week, commenting that the offer substantially undervalues
Allergan have agreed to pay $25 per share in a bid to purchase Mountain View’s neurology group MAP Pharmaceuticals. The per share cash offer signifies a 60% premium over MAP’s closing stock price on January 22nd, and is equal to roughly $958 million. The merger agreement, which is expected to complete during the first or